A Structural Model of Correlated Learning and Late-Mover Advantages: The Case of Statins

References

• Arrow K (1962) Economic welfare and the allocation of resources for invention. Committee on Economic Growth of the Social Science Research Council, eds. The Rate and Direction of Inventive Activity: Economic and Social Factors (Princeton University Press, Princeton, NJ), 609–626.Crossref, Google Scholar
• Azoulay P (2002) Do pharmaceutical sales respond to scientific evidence? J. Econom. Management Strategy 11(4):551–594.Crossref, Google Scholar
• Berndt ER, Bui LT, Lucking-Reiley DH, Urban GL (1996) The roles of marketing, product quality and price competition in the growth and composition of the U.S. antiulcer drug industry. Bresnahan TF, Gordon RJ, eds. The Economics of New Goods, vol. 58 (University of Chicago Press, Chicago), 277–328.Google Scholar
• Chan T, Narasimhan C, Xie Y (2013) Treatment effectiveness and side effects: A model of physician learning. Management Sci. 59(6):1309–1325.Link, Google Scholar
• Ching AT (2010a) A dynamic oligopoly structural model for the prescription drug market after patent expiration. Internat. Econom. Rev. 51(4):1175–1207.Crossref, Google Scholar
• Ching AT (2010b) Consumer learning and heterogeneity: Dynamics of demand for prescription drugs after patent expiration. Internat. J. Indust. Organ. 28(6):619–638.Crossref, Google Scholar
• Ching AT, Ishihara M (2010) The effects of detailing on prescribing decisions under quality uncertainty. Quant. Marketing Econom. 8(2):123–165.Crossref, Google Scholar
• Ching AT, Ishihara M (2012) Measuring the informative and persuasive roles of detailing on prescribing decisions. Management Sci. 58(7):1374–1387.Link, Google Scholar
• Ching AT, Erdem T, Keane M (2009) The price consideration model of brand choice. J. Appl. Econom. 24(3):393–420.Crossref, Google Scholar
• Ching AT, Erdem T, Keane MP (2013) Learning models: An assessment of progress, challenges, and new developments. Marketing Sci. 32(6):913–938.Link, Google Scholar
• Ching AT, Erdem T, Keane MP (2014) A simple method to estimate the roles of learning, inventories and category consideration in consumer choice. J. Choice Model. 13:60–72.Crossref, Google Scholar
• Ching AT, Erdem T, Keane MP (2017) Empirical models of learning dynamics: A survey of recent developments. Wierenga B, van der Lans R, eds. Handbook of Marketing Decision Models, 2nd ed., International Series in Operations Research & Management Science, vol. 254 (Springer, Cham, Switzerland), 223–257.Crossref, Google Scholar
• Ching AT, Erdem T, Keane MP (2019) How much do consumers know about the quality of products? Evidence from the diaper market. Japanese Econom. Rev. Forthcoming.Google Scholar
• Ching AT, Clark RC, Horstmann IJ, Lim H (2016) The effects of publicity on demand: The case of anti-cholesterol drugs. Marketing Sci. 35(1):158–181.Link, Google Scholar
• Chintagunta PK, Renna Jiang R, Jin GZ (2009) Information, learning, and drug diffusion: The case of cox-2 inhibitors. Quant. Marketing Econom. 7(4):399–443.Crossref, Google Scholar
• Cholesterol Treatment Trialists’ Collaborators (2005) Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366(9493):1267–1278.Crossref, Google Scholar
• Cosh C (2010) National pharmacare, as run by omniscient angels. Maclean's (September 18), http://www2.macleans.ca/2010/09/18/national-pharmacare-as-run-by-omniscient-angels/.Google Scholar
• Crawford GS, Shum M (2005) Uncertainty and learning in pharmaceutical demand. Econometrica 73(4):1137–1173.Crossref, Google Scholar
• DeGroot M (1970) Optimal Statistical Decisions (McGraw-Hill, New York).Google Scholar
• Delahoy PJ, Magliano DJ, Webb K, Grobler M, Liew D (2009) The relationship between reduction in low-density lipoprotein cholesterol by statins and reduction in risk of cardiovascular outcomes: An updated meta-analysis. Clinical Therapeutics 31(2):236–244.Crossref, Google Scholar
• Erdem T (1998) An empirical analysis of umbrella branding. J. Marketing Res. 35(3):339–351.Crossref, Google Scholar
• Erdem T, Keane MP (1996) Decision-making under uncertainty: Capturing dynamic brand choice processes in turbulent consumer goods markets. Marketing Sci. 15(1):1–20.Link, Google Scholar
• Erdem T, Sun B (2002) An empirical investigation of spillover effects of marketing mix strategy in umbrella branding. J. Marketing Res. 39(4):408–420.Crossref, Google Scholar
• Gallant AR, Hong H, Khwaja A (2018) The dynamic spillovers of entry: An application to the generic drug industry. Management Sci. 64(3):1189–1211.Link, Google Scholar
• Ghemawat P (1986) Sustainable advantage. Harvard Bus. Rev. 64(5): 53–58.Google Scholar
• Ghemawat P, Spence M (1985) Learning curve spillovers and market performance. Quart. J. Econom. 100(Suppl):839–852.Google Scholar
• Golder PN, Tellis GJ (1993) Pioneer advantage: Marketing logic or marketing legend? J. Marketing Res. 30(2):158–170.Crossref, Google Scholar
• Guasch JL, Weiss A (1980) Wages as sorting mechanisms in competitive markets with asymmetric information: A theory of testing. Rev. Econom. Stud. 47(4):653–664.Crossref, Google Scholar
• Heckman JJ (1981) The incidental parameters problem and the problem of initial condition in estimating a discrete time-discrete data stochastic process. Manski CF, McFadden DL, eds. Structural Analysis of Discrete Data and Econometric Applications (MIT Press, Cambridge, MA), 179–195.Google Scholar
• Janakiraman R, Sismeiro C, Dutta S (2009) Perception spillovers across competing brands: A disaggregate model of how and when. J. Marketing Res. 46(4):467–481.Crossref, Google Scholar
• Law MR, Wald NJ, Rudnicka AR (2003) Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: Systematic review and meta-analysis. BMJ 326(7404):1423.Crossref, Google Scholar
• Leffler KB (1981) Persuasion or information? The economics of prescription drug advertising. J. Law Econom. 24(1):45–74.Crossref, Google Scholar
• Lieberman MB (1987) The learning curve, diffusion, and competitive strategy. Strategic Management J. 8(5):441–452.Crossref, Google Scholar
• Liu H, Liu Q, Chintagunta PK (2017) Promotion spillovers: Drug detailing in combination therapy. Marketing Sci. 36(3):382–401.Link, Google Scholar
• Liu Q, Steenburgh TJ, Gupta S (2015) The cross attributes flexible substitution logit: Uncovering category expansion and share impacts of marketing instruments. Marketing Sci. 34(1):144–159.Link, Google Scholar
• Marcoul P, Weninger Q (2008) Search and active learning with correlated information: Empirical evidence from mid-Atlantic clam fishermen. J. Econom. Dynam. Control 32(6):1921–1948.Crossref, Google Scholar
• Narayanan S, Manchanda P, Chintagunta PK (2005) Temporal differences in the role of marketing communication in new product categories. J. Marketing Res. 42(3):278–290.Crossref, Google Scholar
• Neslin SA, Rhoads EE, Wolfson P (2009) A model and empirical analysis of patient compliance and persistence in pharmaceuticals. Working paper, Dartmouth College, Hanover, NH.Google Scholar
• Park A (2008) Is Vytorin a failure? Time (January 15), http://www.time.com/time/health/article/0,8599,1703827,00.html.Google Scholar
• Reinganum J (1983) Uncertain innovation and the persistence of monopoly. Amer. Econom. Rev. 73(4):741–748.Google Scholar
• Schumpeter JA (1961) The Theory of Economic Development: An Inquiry Into Profits, Capital, Credit, Interest, and the Business Cycle (Oxford University Press, Oxford, UK).Google Scholar
• Shapiro BT (2018) Positive spillovers and free riding in advertising of prescription pharmaceuticals: The case of antidepressants. J. Political Econom. 126(1):381–437.Crossref, Google Scholar
• Simon F, Kotler P (2003) Building Global Biobrands: Taking Biotechnology to Market (Free Press, New York).Google Scholar
• Spence M (1984) Cost reduction, competition, and industry performance. Econometrica 52(1):101–121.Crossref, Google Scholar
• Tang M-J (1988) An economic perspective on escalating commitment. Strategic Management J. 9(S1):79–92.Crossref, Google Scholar
• Zhou Z, Rahme E, Pilote L (2006) Are statins created equal? Evidence from randomized trials of pravastatin, simvastatin, and atorvastatin for cardiovascular disease prevention. Amer. Heart J. 151(2):273–281.Crossref, Google Scholar